|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous observational studies performed over the past few decades have demonstrated the supreme "likability" and abuse and dependence liability/addictiveness of oxycodone, with more recent mechanistic studies illuminating biological underpinnings including markedly increased active transport across the blood-brain barrier, increased phasic dopaminergism in the ventral tegmental area, nucleus accumbens and related striatal reward centers, and possibly increased kappa opioid receptor-mediated withdrawal dysphoria.
|
30820686 |
2019 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Kappa opioid receptor (KOR) agonists produce analgesic and anti-pruritic effects, but their clinical application was limited by dysphoria and hallucinations.
|
30082888 |
2019 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an antipruritus drug with few side effects in humans (e.g., sedation, depression, and dysphoria).
|
30908671 |
2019 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
A main molecular addiction hypothesis is that the upregulation of the dynorphin (DYN)/κ-opioid receptor (KOR) system in the nucleus accumbens (NAc) of alcohol-dependent individuals causes the imbalance in activity of D1- and D2 dopamine receptor (DR) expressing neural circuits that results in dysphoria.
|
29383684 |
2018 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
In normal mice, robust aversions were induced by systemic inflammation, nausea, pain, and κ opioid receptor-induced dysphoria.
|
29911992 |
2018 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several studies have shown that agonists that activate the κ-opioid receptor (KOR) in a manner that favors G protein coupling over β-arrestin2 recruitment in cell culture may represent a means to treat pain and itch while avoiding sedation and dysphoria.
|
30087177 |
2018 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recent study has demonstrated that a G protein-biased agonist for κ-OR provides effective pain and itch relief without causing sedation or dysphoria, in animal models.
|
28110810 |
2017 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
While KOPr agonists induce anhedonia and dysphoria, KOPr antagonists display antidepressant and anxiolytic properties.
|
28550455 |
2017 |
|
Dysphoric mood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesyl Salvinorin B (MSB) is a potent selective kappa opioid receptor (KOP-r) agonist that has potential for development as an anti-psychostimulant agent with fewer side-effects (e.g., sedation, depression and dysphoria) than classic KOP-r agonists.
|
28263712 |
2017 |
|
Dysphoric mood
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Synthetic κ opioid receptor agonists have no abuse liability and well-documented antinociceptive effects; however, adverse effects (diuresis, dysphoria) preclude their use in the clinic.
|
27903642 |
2017 |